(VIANEWS) – Arcturus Therapeutics saw its share price surge 31.7% over 21 sessions from EUR23.94 on November 30th to EUR31.53 on Monday after experiencing a downward trend the previous session. Even as overall NASDAQ decreased 0.56% to EUR15,011.35, Arcturus Therapeutics shares still continued their increase and are currently trading 16.48% below their 52-week high of EUR37.75.
About Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc is a biotechnology company focused on creating messenger RNA (mRNA)-based medicines and vaccines to treat infectious disease vaccines, rare liver, and respiratory conditions. The primary areas of expertise at Arcturus include infectious disease vaccine development as well as products for rare liver and respiratory conditions. Innovative proprietary technology platforms from LUNAR Lipid-Mediated Delivery and STARR MRNA enable the development of mRNA therapeutics. Arcturus Therapeutics currently has three late-stage clinical pipeline candidates under development for ornithine transcarbamylase deficiency: ARCT-810 (LUNAR-OTC), which is in Phase 2 trials; ARCT-154 (LUNAR-COV19), an mRNA vaccine candidate against COVID-19 currently being evaluated in Vietnam through Phase 3/4/3 studies; and ARCT-032 (LUNAR-CF). Arcturus Therapeutics was founded in 2013 and headquartered out of San Diego.
Yearly Analysis
Technical Analysis
Quarter Analysis
According to available data, Arcturus Therapeutics is currently experiencing negative sales growth both for this quarter and for next. Their estimates for both quarters also remain negative.
However, the company has experienced an exponential year-on-year quarterly revenue growth rate over the last twelve trailing months, reaching 296.24M as of January 2019.
Overall, the company’s financial performance appears negative in the short term; however, recent performance indicates significant growth over the course of one year. Investors should carefully consider this information when making investment decisions.
Equity Analysis
Thank you for providing information on Arcturus Therapeutics’ financial performance. Here is a short and concise analysis:
Arcturus Therapeutics currently boasts a trailing twelve month EPS of EUR3.76.
PE Ratio: The company boasts an 8.39 trailing twelve months price to earnings ratio, which indicates investors are paying EUR8.39 for every euro in annual earnings.
Return on Equity (ROE): Arcturus Therapeutics’ 12-month trailing ROE was 46.66%, an impressive figure that indicates they are making substantial profits relative to shareholder’s equity.
Overall, Arcturus Therapeutics appears to be a profitable company with a good return on equity. Investors should carefully consider its growth prospects, industry trends, and other considerations before making their investment decision. Comparing Arcturus Therapeutics’ financial performance against that of its competitors may also prove helpful.
More news about Arcturus Therapeutics (ARCT).
